Skip to main content
Annals of Oncology logoLink to Annals of Oncology
. 2019 Aug 13;30(11):1842. doi: 10.1093/annonc/mdz215

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

G N Hortobagyi, S M Stemmer, H A Burris, Y S Yap, G S Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, E P Winer, W Janni, S Verma, P Conte, C L Arteaga, D A Cameron, S Mondal, F Su, M Miller, M Elmeliegy, C Germa, J O’Shaughnessy
PMCID: PMC6927326  PMID: 31407010

Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155)

The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”


Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES